GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Harvey Jones takes a look at 2 FTSE 100 income stocks that investors are snubbing right now to see whether there's a big ...

(Alliance News) - GSK PLC on Monday said its gepotidacin drug has been accepted for priority review in the US as an oral option for the treatment of a form of sexually transmitted infection gonorrhoea ...

As of 0715 GMT, the blue-chip index FTSE 100 gained 0.3% and the British pound rose 0.09% against the dollar to above 1.34.

Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.

More than 600,000 cases of gonorrhoea were reported in the U.S. in 2023, according to the U.S. Centers for Disease Control and Prevention. There are no vaccine licenses in the U.S. for preventing the ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...